Henry Barreras
University of Miami
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Henry Barreras.
Biology of Blood and Marrow Transplantation | 2017
Dietlinde Wolf; Henry Barreras; Cameron S. Bader; Sabrina Copsel; Casey O. Lightbourn; Brent J. Pfeiffer; Norman H. Altman; Eckhard R. Podack; Krishna V. Komanduri; Robert B. Levy
Regulatory T cells (Tregs) are critical for self-tolerance. Although adoptive transfer of expanded Tregs limits graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT), ex vivo generation of large numbers of functional Tregs remains difficult. Here, we demonstrate that in vivo targeting of the TNF superfamily receptor TNFRSF25 using the TL1A-Ig fusion protein, along with IL-2, resulted in transient but massive Treg expansion in donor mice, which peaked within days and was nontoxic. Tregs increased in multiple compartments, including blood, lymph nodes, spleen, and colon (GVHD target tissue). Tregs did not expand in bone marrow, a critical site for graft-versus-malignancy responses. Adoptive transfer of in vivo-expanded Tregs in the setting of MHC-mismatched or MHC-matched allogeneic HSCT significantly ameliorated GVHD. Critically, transplantation of Treg-expanded donor cells facilitated transplant tolerance without GVHD, with complete sparing of graft-versus-malignancy. This approach may prove valuable as a therapeutic strategy promoting transplantation tolerance.
Journal of Biomolecular Screening | 2012
Claudiu M. Nelersa; Henry Barreras; Erik Runko; Jerome Ricard; Yan Shi; Stephanie J. Glass; John L. Bixby; Vance Lemmon; Daniel J. Liebl
Small-molecule compounds (SMCs) can provide an inexpensive and selective approach to modifying biological responses. High-content analysis (HCA) of SMC libraries can help identify candidate molecules that inhibit or activate cellular responses. In particular, regulation of cell death has important implications for many pathological conditions. Dependence receptors are a new classification of proapoptotic membrane receptors that, unlike classic death receptors, initiate apoptotic signals in the absence of their ligands. EphA4 has recently been identified as a dependence receptor that may have important functions in conditions as disparate as cancer biology and CNS injury and disease. To screen potential candidate SMCs that inhibit or activate EphA4-induced cell death, HCA of an SMC library was performed using stable EphA4-expressing NIH 3T3 cells. Our results describe a high-content method for screening dependence receptor-signaling pathways and demonstrate that several candidate SMCs can inhibit EphA4-mediated cell death.
Immunologic Research | 2013
Robert G. Newman; Duncan B. Ross; Henry Barreras; Samantha Herretes; Eckhard R. Podack; Krishna V. Komanduri; Victor L. Perez; Robert B. Levy
Since its inception in the mid-twentieth century, the complication limiting the application and utility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat patients with hematopoietic cancer is the development of graft-versus-host disease (GVHD). Ironically, GVHD is induced by the cells (T lymphocytes) transplanted for the purpose of eliminating the malignancy. Damage ensuing to multiple tissues, e.g., skin, GI, liver, and others including the eye, provides the challenge of regulating systemic and organ-specific GVH responses. Because the immune system is also targeted by GVHD, this both: (a) impairs reconstitution of immunity post-transplant resulting in patient susceptibility to lethal infection and (b) markedly diminishes the individual’s capacity to generate anti-cancer immunity—the raison d’etre for undergoing allo-HSCT. We hypothesize that deleting alloreactive T cells ex vivo using a new strategy involving antigen stimulation and alkylation will prevent systemic GVHD thereby providing a platform for the generation of anti-tumor immunity. Relapse also remains the major complication following autologous HSCT (auto-HSCT). While GVHD does not complicate auto-HSCT, its absence removes significant grant anti-tumor responses (GVL) and raises the challenge of generating rapid and effective anti-tumor immunity early post-transplant prior to immune reconstitution. We hypothesize that effective vaccine usage to stimulate tumor-specific T cells followed by their amplification using targeted IL-2 can be effective in both the autologous and allogeneic HSCT setting. Lastly, our findings support the notion that the ocular compartment can be locally targeted to regulate visual complications of GVHD which may involve both alloreactive and self-reactive (i.e., autoimmune) responses.
Investigative Ophthalmology & Visual Science | 2015
Samantha Herretes; Duncan B. Ross; Stephanie Duffort; Henry Barreras; Tan Yaohong; Ali M. Saeed; Juan Carlos Murillo; Krishna V. Komanduri; Robert B. Levy; Victor L. Perez
PURPOSE The primary objective of the present study was to identify the kinetics and origin of ocular infiltrating T cells in a preclinical model of graft-versus-host disease (GVHD) that induces eye tissue damage. METHODS Graft-versus-host disease was induced using an major histocompatibility complex (MHC)-matched, minor histocompatibility-mismatched hematopoietic stem cell transplant (HSCT) model. This approach, which utilized congenic and EGFP-labeled donor populations, mimics a matched, clinically unrelated donor (MUD) cell transplant. Systemic and ocular GVHD were assessed at varying time points using clinical examination, intravital microscopy, immune phenotype via flow cytometric analyses, and immunohistochemical staining. RESULTS Following transplant, we observed characteristic changes in GVHD-associated immune phenotype as well as clinical signs present in recipients post transplant. Notably, the kinetics of the systemic changes and the ocular damage paralleled what is observed clinically, including damage to the cornea as well as the conjunctiva and lacrimal gland. Importantly, the infiltrate contained predominantly donor CD4 as well as CD8 T cells with an activated phenotype and macrophages together with effector cytokines consistent with the presence of a TH1 alloreactive population. CONCLUSIONS Overall, the findings here unequivocally demonstrated that donor T cells compose part of the corneal and ocular adnexa infiltrate in animals undergoing ocular GVHD. In total, the results describe a novel and promising preclinical model characterized by both systemic and ocular changes as detected in significant numbers of patients undergoing GVHD following allo-HSCT, which can help facilitate dissecting the underlying immune mechanisms leading to damage associated with ocular GVHD.
JCI insight | 2018
Dietlinde Wolf; Cameron S. Bader; Henry Barreras; Sabrina Copsel; Brent J. Pfeiffer; Casey O. Lightbourn; Norman H. Altman; Krishna V. Komanduri; Robert B. Levy
Posttransplant cyclophosphamide (PTCy) has been found to be effective in ameliorating acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation (aHSCT). Adoptive transfer of high numbers of donor Tregs in experimental aHSCT has shown promise as a therapeutic modality for GVHD regulation. We recently described a strategy for in vivo Treg expansion targeting two receptors: TNFRSF25 and CD25. To date, there have been no direct comparisons between the use of PTCy and Tregs regarding outcome and immune reconstitution within identical groups of transplanted mice. Here, we assessed these two strategies and found both decreased clinical GVHD and improved survival long term. However, recipients transplanted with Treg-expanded donor cells (TrED) exhibited less weight loss early after HSCT. Additionally, TrED recipients demonstrated less thymic damage, significantly more recent thymic emigrants, and more rapid lymphoid engraftment. Three months after HSCT, PTCy-treated and TrED recipients showed tolerance to F1 skin allografts and comparable immune function. Overall, TrED was found superior to PTCy with regard to weight loss early after transplant and initial lymphoid engraftment. Based on these findings, we speculate that morbidity and mortality after transplant could be diminished following TrED transplant into aHSCT recipients, and, therefore, that TrED could provide a promising clinical strategy for GVHD prophylaxis.
Biology of Blood and Marrow Transplantation | 2016
Victor L. Perez; Alexander Barsam; Stephanie Duffort; Maitee Urbieta; Henry Barreras; Casey O. Lightbourn; Krishna V. Komanduri; Robert B. Levy
Biology of Blood and Marrow Transplantation | 2018
Cameron S. Bader; Henry Barreras; Casey O. Lightbourn; Sabrina Copsel; Jeonghyun Ahn; Glen N. Barber; Robert B. Levy
Biology of Blood and Marrow Transplantation | 2018
Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O. Lightbourn; Cameron S. Bader; Warren Alperstein; Krishna V. Komanduri; Robert B. Levy
Biology of Blood and Marrow Transplantation | 2018
Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O. Lightbourn; Cameron S. Bader; Warren Alperstein; Norman H. Altman; Krishna V. Komanduri; Robert B. Levy
Cytotherapy | 2017
Dietlinde Wolf; Henry Barreras; Cameron S. Bader; Sabrina Copsel; Casey O. Lightbourn; Brent J. Pfeiffer; Eckhard R. Podack; Krishna V. Komanduri; Robert B. Levy